CA3102584A1 - Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts - Google Patents

Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts Download PDF

Info

Publication number
CA3102584A1
CA3102584A1 CA3102584A CA3102584A CA3102584A1 CA 3102584 A1 CA3102584 A1 CA 3102584A1 CA 3102584 A CA3102584 A CA 3102584A CA 3102584 A CA3102584 A CA 3102584A CA 3102584 A1 CA3102584 A1 CA 3102584A1
Authority
CA
Canada
Prior art keywords
phenyl
ethoxy
thiazolidine
disease
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102584A
Other languages
English (en)
French (fr)
Inventor
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Estefania TRAVER LOPEZ
Ana Maria Garcia Collazo
Maria Angeles Perez De La Cruz Moreno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CA3102584A1 publication Critical patent/CA3102584A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3102584A 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts Pending CA3102584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382402.8 2018-06-06
EP18382402 2018-06-06
PCT/IB2019/054744 WO2019234690A1 (en) 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Publications (1)

Publication Number Publication Date
CA3102584A1 true CA3102584A1 (en) 2019-12-12

Family

ID=62716011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102584A Pending CA3102584A1 (en) 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Country Status (14)

Country Link
US (2) US20210228558A1 (enExample)
EP (1) EP3801517A1 (enExample)
JP (1) JP7510170B2 (enExample)
KR (1) KR20210031867A (enExample)
CN (1) CN112823004A (enExample)
AU (1) AU2019283650A1 (enExample)
BR (1) BR112020024939A2 (enExample)
CA (1) CA3102584A1 (enExample)
CL (1) CL2020003163A1 (enExample)
EA (1) EA202092954A1 (enExample)
IL (1) IL279186A (enExample)
MX (1) MX2020013182A (enExample)
SG (1) SG11202012095XA (enExample)
WO (1) WO2019234690A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
CN116390725A (zh) * 2020-04-30 2023-07-04 米尼奥尔克斯治疗有限公司 用于治疗肺部炎症和间质性肺病的羟基吡格列酮
WO2022243435A1 (en) * 2021-05-19 2022-11-24 Abliva Ab Kl1333 for use in medicine
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3579049B2 (ja) 1992-04-30 2004-10-20 インスティチュート・パスツール Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓにおける抗生物質耐性の迅速検出法
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
AU2012203941A1 (en) * 2006-06-27 2012-07-26 Sandoz Ag New method for salt preparation
EP2436381A1 (en) * 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法

Also Published As

Publication number Publication date
MX2020013182A (es) 2021-02-26
EA202092954A1 (ru) 2021-04-08
JP2021527061A (ja) 2021-10-11
SG11202012095XA (en) 2021-01-28
WO2019234690A1 (en) 2019-12-12
IL279186A (en) 2021-01-31
CL2020003163A1 (es) 2021-07-02
BR112020024939A2 (pt) 2021-03-09
AU2019283650A1 (en) 2021-01-07
US20240091210A1 (en) 2024-03-21
CN112823004A (zh) 2021-05-18
JP7510170B2 (ja) 2024-07-03
KR20210031867A (ko) 2021-03-23
EP3801517A1 (en) 2021-04-14
US20210228558A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US20240091210A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
AU2015239112C1 (en) 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
US20160074364A1 (en) Pyrazole-amide compounds and pharmaceutical use thereof
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
JP7549344B2 (ja) 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
EP3548026B1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
US20200317620A1 (en) Selective inhibition of gluconeogenic activity
EP3712139A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
US11771685B2 (en) Compounds for the treatment of neurological or mitochondrial diseases
EA047194B1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
HK40042762A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
HK40049546A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
EA047277B1 (ru) Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK1245796A1 (en) Xanthine derivative

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250210

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251121

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260720